Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy_West China Medical Journal

Authors：

 GAOLi ,  FANGXiang-ming , YEWen-chun , HUANGJing , WANGYu-rong

Department of Endocrinology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P. R. China;

Corresponding author：

FANGXiang-ming, Email: fsm2002@sina.com

Keywords：

Type-2 diabetes mellitus; Diabetic peripheral neuropathy; Pancreatic kinionogenase enteric-coated tab; Methylcobalamin injection; Nerve conduction velocity

DOI：

10.7507/1002-0179.20140441

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the effect of combined treatment using pancreatic kinionogenase enteric-coated tab and mecobalamin injection on diabetic peripheral neuropathy (DPN) patients. Methods We collected 84 subjects with DPN who received treatment from January 2012 to December 2012 in our hospital, and we randomly divided them into treatment group (42 subjects, using pancreatic kinionogenase enteric-coated tab and methylcobalamin injection) and control group (42 subjects, using mecobalamine only). Subjects in the treatment group were given oral pancreatic kininogenase at 120 unit/times and 3 times/day, and methylcobalamin intravenous injection at 1 mg/day for 14 days. Subjects in the control group were only given methylcobalamin intravenous injection at 1 mg/day for 14 days. Results In the treatment group, 22 subjects showed excellent, 19 subjects effective and 1 subject ineffective outcome. In the control group, 8 subjects showed excellent, 22 effective and 12 ineffective outcome. The difference between the two groups is statistically significant (P<0.01). Compared with no treatment, the nerve conduction velocity in both the two groups has been improved. The improvement in the treatment group is significantly better than that of the control group (P<0.01), and all of them had no obvious adverse reaction during the treatment. Conclusion The combined treatment using pancreatic kinionogenase enteric-coated tab and methylcobalamin injection on DPN is better than using methylcobalamin only.

Citation： GAOLi, FANGXiang-ming, YEWen-chun, HUANGJing, WANGYu-rong. Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy. West China Medical Journal, 2014, 29(8): 1432-1434. doi: 10.7507/1002-0179.20140441 Copy

1.	姚合斌, 潘长玉, 陆思珍, 等. 激肽系统在实验性糖尿病肾病发展中的作用研究[J]. 中国糖尿病杂志, 2000, 8(6):356-359.
2.	Little AA, Edwards JL, Feldman EL. Diabetic neuropathies[J]. Pract Neurol, 2007, 7(2):82-92.
3.	任丽平, 姜喆, 赵颖, 等. 怡开治疗30例糖尿病肾病临床分析[J]. 长春中医学院学报, 2004, 20(1):13.
4.	张华珍, 苏言辉, 陈秋. 银杏达莫联合甲钴胺治疗糖尿病周围神经病变的临床分析[J]. 中国综合临床, 2010, 26(4):383-385.
5.	傅汉菁, 袁申元. 胰激肽原酶在糖尿病治疗中的临床应用[J]. 中国实用内科杂志, 2004, 24(11):698-700.
6.	Foster TS. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy[J]. Diabetes Educ, 2007, 33(1):111-117.
7.	American Diabetes Association. Implication of the United Kingdom prospective diabetes study[J]. Diabetes Care, 1998, 21(12):2180-2184.
8.	柴伟栋, 陈家伟. 微循环与糖尿病微血管病变[J]. 中国微循环, 2000, 4(2):130-132.
9.	KawamuraM, OharaH, GoK, et al. Newrotropini ndues antinociceptive effet by enbancing descending pain inhibitory systems involving 5-HT 3 and nora-drenergic alpha 2 receptors in spinal dorsal horn[J]. Life Sci, 1998, 62(11):2181.
10.	Hotta N, Koh N, Sakakibara F, et al. Neurotropin prevents neurophysiological abnormalities and ADP-induced hyperaggregability in rats with streptozotocin-induced diabetes[J]. Life Sci, 1995, 57(23):2101-2111.
11.	王颖, 丁颜. 弥可保改善糖尿病周围神经病变疗效观察[J]. 中国医师杂志, 2002, 4(9):1028-1028.
12.	范本. 依帕司他治疗早期糖尿病肾病36例疗效观察[J]. 山东医药, 2011, 51(29):95-96.
13.	韩隆元. 硫辛酸与依帕司他联合门冬胰岛素30治疗2型糖尿病周围神经病变疗效观察[J]. 中国医药, 2012, 7(2):163-165.
14.	李建波, 陈家伟. 糖尿病神经病变的发病机理及其现代认识[J]. 实用糖尿病杂志, 1997, 5(1):3-5.
15.	孟柳, 朱筠. 2型糖尿病周围神经病变与血清TAOC、MDA、SOD相关性研究[J]. 实用糖尿病杂志, 2011, 7(5):18-19.
16.	王桂侠, 李广仁, 刘立, 等. 糖尿病周围神经病变患者神经病理及临床研究[J]. 中风与神经疾病杂志, 2000, 17(5):277-279.

1. 姚合斌, 潘长玉, 陆思珍, 等. 激肽系统在实验性糖尿病肾病发展中的作用研究[J]. 中国糖尿病杂志, 2000, 8(6):356-359.
2. Little AA, Edwards JL, Feldman EL. Diabetic neuropathies[J]. Pract Neurol, 2007, 7(2):82-92.
3. 任丽平, 姜喆, 赵颖, 等. 怡开治疗30例糖尿病肾病临床分析[J]. 长春中医学院学报, 2004, 20(1):13.
4. 张华珍, 苏言辉, 陈秋. 银杏达莫联合甲钴胺治疗糖尿病周围神经病变的临床分析[J]. 中国综合临床, 2010, 26(4):383-385.
5. 傅汉菁, 袁申元. 胰激肽原酶在糖尿病治疗中的临床应用[J]. 中国实用内科杂志, 2004, 24(11):698-700.
6. Foster TS. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy[J]. Diabetes Educ, 2007, 33(1):111-117.
7. American Diabetes Association. Implication of the United Kingdom prospective diabetes study[J]. Diabetes Care, 1998, 21(12):2180-2184.
8. 柴伟栋, 陈家伟. 微循环与糖尿病微血管病变[J]. 中国微循环, 2000, 4(2):130-132.
9. KawamuraM, OharaH, GoK, et al. Newrotropini ndues antinociceptive effet by enbancing descending pain inhibitory systems involving 5-HT 3 and nora-drenergic alpha 2 receptors in spinal dorsal horn[J]. Life Sci, 1998, 62(11):2181.
10. Hotta N, Koh N, Sakakibara F, et al. Neurotropin prevents neurophysiological abnormalities and ADP-induced hyperaggregability in rats with streptozotocin-induced diabetes[J]. Life Sci, 1995, 57(23):2101-2111.
11. 王颖, 丁颜. 弥可保改善糖尿病周围神经病变疗效观察[J]. 中国医师杂志, 2002, 4(9):1028-1028.
12. 范本. 依帕司他治疗早期糖尿病肾病36例疗效观察[J]. 山东医药, 2011, 51(29):95-96.
13. 韩隆元. 硫辛酸与依帕司他联合门冬胰岛素30治疗2型糖尿病周围神经病变疗效观察[J]. 中国医药, 2012, 7(2):163-165.
14. 李建波, 陈家伟. 糖尿病神经病变的发病机理及其现代认识[J]. 实用糖尿病杂志, 1997, 5(1):3-5.
15. 孟柳, 朱筠. 2型糖尿病周围神经病变与血清TAOC、MDA、SOD相关性研究[J]. 实用糖尿病杂志, 2011, 7(5):18-19.
16. 王桂侠, 李广仁, 刘立, 等. 糖尿病周围神经病变患者神经病理及临床研究[J]. 中风与神经疾病杂志, 2000, 17(5):277-279.

West China Medical Journal

Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content